Van Lanschot Kempen Investment Management N.V. Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Van Lanschot Kempen Investment Management N.V. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 328,640 shares of the biopharmaceutical company's stock after selling 174,174 shares during the period. Van Lanschot Kempen Investment Management N.V.'s holdings in Gilead Sciences were worth $30,356,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of GILD. FMR LLC lifted its holdings in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP increased its position in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC raised its stake in Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Norges Bank bought a new stake in Gilead Sciences in the fourth quarter worth $1,789,254,000. Finally, Invesco Ltd. grew its stake in shares of Gilead Sciences by 12.9% in the fourth quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock worth $1,041,741,000 after acquiring an additional 1,292,399 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.23 on Thursday, hitting $106.15. 10,119,607 shares of the stock traded hands, compared to its average volume of 7,533,862. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The firm has a 50 day simple moving average of $109.21 and a two-hundred day simple moving average of $97.88. The firm has a market cap of $132.17 billion, a price-to-earnings ratio of 286.89, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is 854.05%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 302,785 shares of company stock valued at $30,540,875. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on GILD shares. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday. They set an "overweight" rating and a $125.00 price target for the company. Finally, Morgan Stanley upped their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research report on Tuesday, March 11th. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $106.92.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.